Note 3 - Balance Sheet Details

3 Months Ended

Mar. 31, 2023

Disclosure Text Block [Abstract]

Balance Sheet Details

3. Balance Sheet Details

Prepaid expenses and other current assets consisted of the following (in thousands):

	March 31,		December 31,
	2023		2022
Prepaid insurance	$	355	$	581
Other receivables		78		1,438
Prepaid subscriptions and fees		193		157
Prepaid software licenses		37		54
Deferred equity issuance costs		93		114
Prepaid other		6		6
	$	762	$	2,350

Other receivables as of March 31, 2023 and December 31, 2022 includes a $47,600 receivable and $1.4 million receivable, respectively, for the cash exercise price of common stock purchase warrants that had been exercised but the cash had not yet been received by the Company as of each respective balance sheet date. The entire amount of these other receivables as of March 31, 2023 and December 31, 2022 were received in April 2023 and January 2023, respectively.

Other noncurrent assets consisted of the following (in thousands):

	March 31,		December 31,
	2023		2022
Prepaid insurance, less current portion	$	631	$	682
Other noncurrent assets		12		12
	$	643	$	694

Accrued liabilities consisted of the following (in thousands):

	March 31,		December 31,
	2023		2022
Accrued accounts payable	$	73	$	69
Accrued clinical trial costs		94		184
Accrued director stipends		108		141
Accrued severance and benefits (Note 9)		5		180
Accrued other		29		—
	$	309	$	574